This ‘Gastro-esophageal Adenocarcinoma-Epidemiology Forecast-2030' report delivers an in-depth understanding of the Gastro-esophageal Adenocarcinoma, historical and forecasted epidemiology as well as the Gastro-esophageal Adenocarcinoma trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Gastroesophageal adenocarcinoma includes esophageal adenocarcinoma, gastroesophageal junctional adenocarcinoma, and gastric adenocarcinoma. There is an increasing trend in the incidence of these cancers in the 7MM.
Gastroesophageal cancer (GEC), comprising proximal esophagogastric junction (EGJ) and distal gastric cancer (GC), is a significant public health concern. The epidemiology of these tumors has significantly changed over the past several decades especially in developed countries. There is a recognized decrease in incidence and mortality of distal GC and an increase in incidence and mortality of proximal EGJ cancer.
Anatomically, gastroesophageal cancer (GEC) is comprised of two recognized tumor types, according to the 2010 American Joint Committee on Cancer (AJCC) TNM staging system. The first is esophageal/esophagogastric adenocarcinoma, herein referred to as EGJ cancers, entailing tumors arising between 5 cm proximal to the z-line (the endoscopic landmark demarcating the esophagus/stomach boundary) and 5 cm distal to the z-line into the stomach (gastric cardia). The EGJ encompasses the traditional Siewert EGJ classifications I, II, and III. Type I Siewert EGJ is considered esophageal adenocarcinoma. The second recognized tumor type is gastric adenocarcinoma (GC), also termed ‘non-cardia' GC, referring to tumors arising anywhere 5 cm distal from the z-line to the pylorus.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incident Cases of Gastro-esophageal Adenocarcinoma, Gender-specific Incident Cases of Gastro-esophageal Adenocarcinoma, Stage-specific Incident Cases of Gastro-esophageal Adenocarcinoma, Grade-specific Incident Cases of Gastro-esophageal Adenocarcinoma, and HER2 Positive Incident Cases of Gastro-esophageal Adenocarcinoma in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.
The Gastro-esophageal Adenocarcinoma report will allow the user to -
Study Period: 2018-2030
Gastro-esophageal Adenocarcinoma Understanding
Gastroesophageal adenocarcinoma includes esophageal adenocarcinoma, gastroesophageal junctional adenocarcinoma, and gastric adenocarcinoma. There is an increasing trend in the incidence of these cancers in the 7MM.
Gastroesophageal cancer (GEC), comprising proximal esophagogastric junction (EGJ) and distal gastric cancer (GC), is a significant public health concern. The epidemiology of these tumors has significantly changed over the past several decades especially in developed countries. There is a recognized decrease in incidence and mortality of distal GC and an increase in incidence and mortality of proximal EGJ cancer.
Anatomically, gastroesophageal cancer (GEC) is comprised of two recognized tumor types, according to the 2010 American Joint Committee on Cancer (AJCC) TNM staging system. The first is esophageal/esophagogastric adenocarcinoma, herein referred to as EGJ cancers, entailing tumors arising between 5 cm proximal to the z-line (the endoscopic landmark demarcating the esophagus/stomach boundary) and 5 cm distal to the z-line into the stomach (gastric cardia). The EGJ encompasses the traditional Siewert EGJ classifications I, II, and III. Type I Siewert EGJ is considered esophageal adenocarcinoma. The second recognized tumor type is gastric adenocarcinoma (GC), also termed ‘non-cardia' GC, referring to tumors arising anywhere 5 cm distal from the z-line to the pylorus.
Gastro-esophageal Adenocarcinoma Epidemiology Perspective
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incident Cases of Gastro-esophageal Adenocarcinoma, Gender-specific Incident Cases of Gastro-esophageal Adenocarcinoma, Stage-specific Incident Cases of Gastro-esophageal Adenocarcinoma, Grade-specific Incident Cases of Gastro-esophageal Adenocarcinoma, and HER2 Positive Incident Cases of Gastro-esophageal Adenocarcinoma in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.
Gastro-esophageal Adenocarcinoma Detailed Epidemiology Segmentation
- As per this analysis, there was a total of 211,383 Gastro-esophageal Adenocarcinoma incident cases in 2020, increasing at a CAGR of 1.54% for the study period 2018-2030.
- Japan showed the highest incident population of Gastro-esophageal Adenocarcinomas, as compared to other 7MM countries in 2020 which was 115,627.
- Among the European 5 countries, Germany had the highest incident population of Gastro-esophageal Adenocarcinoma with 13,881 cases, followed by the United Kingdom with 13,366 cases, in 2020.
- The epidemiology model for Gastro-esophageal Adenocarcinoma estimates that out of the total incident population of 40,423 cases in the US, in 2020, 29,480 and 10,943 cases were contributed by males and females, respectively.
- In 2020, the incident cases of Gastro-esophageal Adenocarcinoma in Stage IV were 18,318. Remaining Stage I, Stage II, and Stage III contributed to 6,872, 5,838, and 7,793 cases from the total incident cases.
- In 2020, the grade-specific incident cases for Grade I, Grade II, Grade III, and Grade IV were 1,617, 10,237, 25,284, and 808, in the US.
- HER2 positive Gastro-esophageal Adenocarcinomas was found in 7,648 incident cases in the United States, in 2020.
Scope of the Report
- The report covers the descriptive overview of Gastro-esophageal Adenocarcinoma, explaining its causes, genomics, staging, and other parameters.
- The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
- The report assesses the disease risk and burden and highlights the unmet needs of Gastro-esophageal Adenocarcinoma.
- The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
- The report provides the segmentation of the disease epidemiology for 7MM by Total Incident Cases of Gastro-esophageal Adenocarcinoma, Gender-specific Incident Cases of Gastro-esophageal Adenocarcinoma, Stage-specific Incident Cases of Gastro-esophageal Adenocarcinoma, Grade-specific Incident Cases of Gastro-esophageal Adenocarcinoma, and HER2 Positive Incident Cases of Gastro-esophageal Adenocarcinoma.
Report Highlights
- 10-Year Forecast of Gastro-esophageal Adenocarcinoma
- 7MM Coverage
- Total Incident Cases of Gastro-esophageal Adenocarcinoma
- Gender-specific Incident Cases of Gastro-esophageal Adenocarcinoma
- Stage-specific Incident Cases of Gastro-esophageal Adenocarcinoma
- Grade-specific Incident Cases of Gastro-esophageal Adenocarcinoma
- HER2 Positive Incident Cases of Gastro-esophageal Adenocarcinoma
Key Questions Answered
- What are the disease risk, burdens, and unmet needs of Gastro-esophageal Adenocarcinoma?
- What is the historical Gastro-esophageal Adenocarcinoma patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
- What would be the forecasted patient pool of Gastro-esophageal Adenocarcinoma at the 7MM level?
- What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Gastro-esophageal Adenocarcinoma?
- Out of the above-mentioned countries, which country would have the highest incident population of Gastro-esophageal Adenocarcinoma during the forecast period (2021-2030)?
- At what CAGR the population is expected to grow across the 7MM during the forecast period (2021-2030)?
Reasons to Buy
The Gastro-esophageal Adenocarcinoma report will allow the user to -
- Develop business strategies by understanding the trends shaping and driving the 7MM Gastro-esophageal Adenocarcinoma epidemiology forecast.
- The Gastro-esophageal Adenocarcinoma epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
- The Gastro-esophageal Adenocarcinoma epidemiology model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the eleven-year forecast period using reputable sources.
Key Assessments
- Patient Segmentation
- Disease Risk and Burden
- Risk of disease by the segmentation
- Factors driving growth in a specific patient population
Geographies Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Study Period: 2018-2030
Table of Contents
1. Key Insights2. Executive Summary of Gastro-esophageal Adenocarcinoma
3. Gastro-esophageal Adenocarcinoma: Epidemiology Overview at a Glance
3.1. Epidemiology Share (%) by Country of Gastro-esophageal Adenocarcinoma in 2018
3.2. Epidemiology Share (%) by Country of Gastro-esophageal Adenocarcinoma in 2030
4. Gastro-esophageal Adenocarcinoma: Disease Background and Overview
4.1. Introduction
4.2. Causes of Gastro-esophageal Adenocarcinoma
4.2.1. Hereditary Cancer Predisposition Syndromes Associated with an Increased Risk for Esophageal and EGJ Cancers
4.2.2. Hereditary Cancer Predisposition Syndromes Associated with an Increased Risk for Esophageal and EGJ Cancers
4.2.3. Other risk factors
4.3. Genomics in Gastro-esophageal Adenocarcinoma
4.3.1. Disease Classification in the Pregenomic Era
4.3.2. Molecular Classification in the Genomics Era
4.4. Staging of Gastric Cancer
4.5. Staging of Esophageal Cancer
4.6. Diagnosis of Gastric Cancer
4.6.1. Genetic risk assessment
4.6.2. Routine blood tests
4.6.3. Imaging tests
4.6.4. Endoscopic resection
4.6.5. Laparoscopy with cytology
4.6.6. Biopsy of metastases
4.6.7. Biomarker testing
4.7. Diagnosis of Esophageal Cancer
4.7.1. Blood tests
4.7.2. CT scan
4.7.3. PET/CT scan
4.7.4. Upper endoscopy and biopsy
4.7.5. Endoscopic ultrasound
4.7.6. Bronchoscopy
4.7.7. Laparoscopy
4.7.8. Tumor biomarker testing
4.8. Diagnostic Guidelines for Gastric Cancer
4.8.1. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up
4.9. Diagnostic Guidelines for Esophageal Cancer
4.9.1. Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up
4.9.2. The Society of Thoracic Surgeons Guidelines on the Diagnosis and Staging of Patients with Esophageal Cancer
5. Epidemiology and Patient Population
5.1. Key Findings
5.2. Methodology
5.3. Trends of Epidemiology in Gastro-esophageal Adenocarcinoma
5.4. Total Incident Cases of Gastro-esophageal Adenocarcinoma in the 7MM
6. United States Epidemiology
6.1. Assumptions and Rationale
6.2. Total Incident Cases of Gastro-esophageal Adenocarcinoma in the United States
6.3. Gender-specific Incident Cases of Gastro-esophageal Adenocarcinoma in the United States
6.4. Stage-specific Incident Cases of Gastro-esophageal Adenocarcinoma in the US
6.5. Grade-specific Incident Cases of Gastro-esophageal Adenocarcinoma in the US
6.6. HER2 Positive Incident Cases of Gastro-esophageal Adenocarcinoma in the US
7. EU5 Epidemiology
7.1. Assumptions and Rationale
7.2. Germany
7.2.1. Total Incident Cases of Gastro-esophageal Adenocarcinoma in Germany
7.2.2. Gender-specific Incident Cases of Gastro-esophageal Adenocarcinoma in Germany
7.2.3. Stage-specific Incident Cases of Gastro-esophageal Adenocarcinoma in Germany
7.2.4. Grade-specific Incident Cases of Gastro-esophageal Adenocarcinoma in Germany
7.2.5. HER2 Positive Incident Cases of Gastro-esophageal Adenocarcinoma in Germany
7.3. France
7.3.1. Total Incident Cases of Gastro-esophageal Adenocarcinoma in France
7.3.2. Gender-specific Incident Cases of Gastro-esophageal Adenocarcinoma in France
7.3.3. Stage-specific Incident Cases of Gastro-esophageal Adenocarcinoma in France
7.3.4. Grade-specific Incident Cases of Gastro-esophageal Adenocarcinoma in France
7.3.5. HER2 Positive Incident Cases of Gastro-esophageal Adenocarcinoma in France
7.4. Italy
7.4.1. Total Incident Cases of Gastro-esophageal Adenocarcinoma in Italy
7.4.2. Gender-specific Incident Cases of Gastro-esophageal Adenocarcinoma in Italy
7.4.3. Stage-specific Incident Cases of Gastro-esophageal Adenocarcinoma in Italy
7.4.4. Grade-specific Incident Cases of Gastro-esophageal Adenocarcinoma in Italy
7.4.5. HER2 Positive Incident Cases of Gastro-esophageal Adenocarcinoma in Italy
7.5. Spain
7.5.1. Total Incident Cases of Gastro-esophageal Adenocarcinoma in Spain
7.5.2. Gender-specific Incident Cases of Gastro-esophageal Adenocarcinoma in Spain
7.5.3. Stage-specific Incident Cases of Gastro-esophageal Adenocarcinoma in Spain
7.5.4. Grade-specific Incident Cases of Gastro-esophageal Adenocarcinoma in Spain
7.5.5. HER2 Positive Incident Cases of Gastro-esophageal Adenocarcinoma in Spain
7.6. United Kingdom
7.6.1. Total Incident Cases of Gastro-esophageal Adenocarcinoma in the United Kingdom
7.6.2. Gender-specific Incident Cases of Gastro-esophageal Adenocarcinoma in the United Kingdom
7.6.3. Stage-specific Incident Cases of Gastro-esophageal Adenocarcinoma in the UK
7.6.4. Grade-specific Incident Cases of Gastro-esophageal Adenocarcinoma in the UK
7.6.5. HER2 Positive Incident Cases of Gastro-esophageal Adenocarcinoma in the UK
8. Japan Epidemiology
8.1. Assumptions and Rationale
8.2. Total Incident Cases of Gastro-esophageal Adenocarcinoma in Japan
8.3. Gender-specific Incident Cases of Gastro-esophageal Adenocarcinoma in Japan
8.4. Stage-specific Incident Cases of Gastro-esophageal Adenocarcinoma in Japan
8.5. Grade-specific Incident Cases of Gastro-esophageal Adenocarcinoma in Japan
8.6. HER2 Positive Incident Cases of Gastro-esophageal Adenocarcinoma in Japan
9. Appendix
9.1. Bibliography
9.2. Report Methodology
10. Publisher Capabilities
11. Disclaimer
12. About the PublisherList of Tables
Table 1 Summary of Gastroesophageal Adenocarcinoma, Epidemiology and Key Events (2018-2030)
Table 2 Promising future biomarkers
Table 3 Staging of Gastric Cancer
Table 4 Esophageal Adenocarcinoma stages
Table 5 Total Incident Cases of Gastro-esophageal Adenocarcinoma in the 7MM (2018-2030)
Table 6 Total Incident Cases of Gastro-esophageal Adenocarcinoma in the US (2018-2030)
Table 7 Gender-specific Incident Cases of Gastro-esophageal Adenocarcinoma in the US (2018-2030)
Table 8 Stage-specific Incident Cases of Gastro-esophageal Adenocarcinoma in the US (2018-2030)
Table 9 Grade-specific Incident Cases of Gastro-esophageal Adenocarcinoma in the US (2018-2030)
Table 10 HER2 Positive Incident Cases of Gastro-esophageal Adenocarcinoma in the US (2018-2030)
Table 11 Total Incident Cases of Gastro-esophageal Adenocarcinoma in Germany (2018-2030)
Table 12 Gender-specific Incident Cases of Gastro-esophageal Adenocarcinoma in Germany (2018-2030)
Table 13 Stage-specific Incident Cases of Gastro-esophageal Adenocarcinoma in Germany (2018-2030)
Table 14 Grade-specific Incident Cases of Gastro-esophageal Adenocarcinoma in Germany (2018-2030)
Table 15 HER2 Positive Incident Cases of Gastro-esophageal Adenocarcinoma in Germany (2018-2030)
Table 16 Total Incident Cases of Gastro-esophageal Adenocarcinoma in France (2018-2030)
Table 17 Gender-specific Incident Cases of Gastro-esophageal Adenocarcinoma in France (2018-2030)
Table 18 Stage-specific Incident Cases of Gastro-esophageal Adenocarcinoma in France (2018-2030)
Table 19 Grade-specific Incident Cases of Gastro-esophageal Adenocarcinoma in France (2018-2030)
Table 20 HER2 Positive Incident Cases of Gastro-esophageal Adenocarcinoma in France (2018-2030)
Table 21 Total Incident Cases of Gastro-esophageal Adenocarcinoma in Italy (2018-2030)
Table 22 Gender-specific Incident Cases of Gastro-esophageal Adenocarcinoma in Italy (2018-2030)
Table 23 Stage-specific Incident Cases of Gastro-esophageal Adenocarcinoma in Italy (2018-2030)
Table 24 Grade-specific Incident Cases of Gastro-esophageal Adenocarcinoma in Italy (2018-2030)
Table 25 HER2 Positive Incident Cases of Gastro-esophageal Adenocarcinoma in Italy (2018-2030)
Table 26 Total Incident Cases of Gastro-esophageal Adenocarcinoma in Spain (2018-2030)
Table 27 Gender-specific Incident Cases of Gastro-esophageal Adenocarcinoma in Spain (2018-2030)
Table 28 Stage-specific Incident Cases of Gastro-esophageal Adenocarcinoma in Spain (2018-2030)
Table 29 Grade-specific Incident Cases of Gastro-esophageal Adenocarcinoma in Spain (2018-2030)
Table 30 HER2 Positive Incident Cases of Gastro-esophageal Adenocarcinoma in Spain (2018-2030)
Table 31 Total Incident Cases of Gastro-esophageal Adenocarcinoma in the UK (2018-2030)
Table 32 Gender-specific Incident Cases of Gastro-esophageal Adenocarcinoma in the UK (2018-2030)
Table 33 Stage-specific Incident Cases of Gastro-esophageal Adenocarcinoma in the UK (2018-2030)
Table 34 Grade-specific Incident Cases of Gastro-esophageal Adenocarcinoma in the UK (2018-2030)
Table 35 HER2 Positive Incident Cases of Gastro-esophageal Adenocarcinoma in the UK (2018-2030)
Table 36 Total Incident Cases of Gastro-esophageal Adenocarcinoma in Japan (2018-2030)
Table 37 Gender-specific Incident Cases of Gastro-esophageal Adenocarcinoma in Japan (2018-2030)
Table 38 Stage-specific Incident Cases of Gastro-esophageal Adenocarcinoma in Japan (2018-2030)
Table 39 Grade-specific Incident Cases of Gastro-esophageal Adenocarcinoma in Japan (2018-2030)
Table 40 HER2 Positive Incident Cases of Gastro-esophageal Adenocarcinoma in Japan (2018-2030)List of Figures
Figure 1 Gastro-esophageal cancer with anatomical subdivision into gastric adenocarcinoma and esophagogastric adenocarcinoma with Siewert classification
Figure 2 Helicobactor pylori exert oncogenic effects on the gastric epithelium that can result in gastric adenocarcinoma
Figure 3 Molecular classification of GEA. Key features of the four TCGA subtypes of GEA spanning the lower esophagus to the distal stomach
Figure 4 Types of genomic heterogeneity in GEA.
Figure 5 Molecular classification of gastric adenocarcinoma
Figure 6 Gastric Layers
Figure 7 The stages of stomach cancer
Figure 8 Esophageal tumor growth chart
Figure 9 Total Incident Cases of Gastro-esophageal Adenocarcinoma in the 7MM (2018-2030)
Figure 10 Total Incident cases of Gastro-esophageal Adenocarcinoma in the US (2018-2030)
Figure 11 Gender-specific Incident Cases of Gastro-esophageal Adenocarcinoma in the US (2018-2030)
Figure 12 Stage-specific Incident Cases of Gastro-esophageal Adenocarcinoma in the US (2018-2030)
Figure 13 Grade-specific Incident Cases of Gastro-esophageal Adenocarcinoma in the US (2018-2030)
Figure 14 HER2 Positive Incident Cases of Gastro-esophageal Adenocarcinoma in the US (2018-2030)
Figure 15 Total Incident Cases of Gastro-esophageal Adenocarcinoma in Germany (2018-2030)
Figure 16 Gender-specific Incident Cases of Gastro-esophageal Adenocarcinoma in Germany (2018-2030)
Figure 17 Stage-specific Incident Cases of Gastro-esophageal Adenocarcinoma in Germany (2018-2030)
Figure 18 Grade-specific Incident Cases of Gastro-esophageal Adenocarcinoma in Germany (2018-2030)
Figure 19 HER2 Positive Incident Cases of Gastro-esophageal Adenocarcinoma in Germany (2018-2030)
Figure 20 Total Incident cases of Gastro-esophageal Adenocarcinoma in France (2018-2030)
Figure 21 Gender-specific Incident Cases of Gastro-esophageal Adenocarcinoma in France (2018-2030)
Figure 22 Stage-specific Incident Cases of Gastro-esophageal Adenocarcinoma in France (2018-2030)
Figure 23 Grade-specific Incident Cases of Gastro-esophageal Adenocarcinoma in France (2018-2030)
Figure 24 HER2 Positive Incident Cases of Gastro-esophageal Adenocarcinoma in France(2018-2030)
Figure 25 Total Incident cases of Gastro-esophageal Adenocarcinoma in Italy (2018-2030)
Figure 26 Gender-specific Incident Cases of Gastro-esophageal Adenocarcinoma in Italy (2018-2030)
Figure 27 Stage-specific Incident Cases of Gastro-esophageal Adenocarcinoma in Italy (2018-2030)
Figure 28 Grade-specific Incident Cases of Gastro-esophageal Adenocarcinoma in Italy (2018-2030)
Figure 29 HER2 Positive Incident Cases of Gastro-esophageal Adenocarcinoma in Italy (2018-2030)
Figure 30 Total Incident cases of Gastro-esophageal Adenocarcinoma in Spain (2018-2030)
Figure 31 Gender-specific Incident Cases of Gastro-esophageal Adenocarcinoma in Spain (2018-2030)
Figure 32 Stage-specific Incident Cases of Gastro-esophageal Adenocarcinoma in Spain (2018-2030)
Figure 33 Grade-specific Incident Cases of Gastro-esophageal Adenocarcinoma in Spain (2018-2030)
Figure 34 HER2 Positive Incident Cases of Gastro-esophageal Adenocarcinoma in Spain (2018-2030)
Figure 35 Total Incident cases of Gastro-esophageal Adenocarcinoma in the UK (2018-2030)
Figure 36 Gender-specific Incident Cases of Gastro-esophageal Adenocarcinoma in the UK (2018-2030)
Figure 37 Stage-specific Incident Cases of Gastro-esophageal Adenocarcinoma in the UK (2018-2030)
Figure 38 Grade-specific Incident Cases of Gastro-esophageal Adenocarcinoma in the UK (2018-2030)
Figure 39 HER2 Positive Incident Cases of Gastro-esophageal Adenocarcinoma in the UK (2018-2030)
Figure 40 Total Incident cases of Gastro-esophageal Adenocarcinoma in Japan (2018-2030)
Figure 41 Gender-specific Incident Cases of Gastro-esophageal Adenocarcinoma in Japan (2018-2030)
Figure 42 Stage-specific Incident Cases of Gastro-esophageal Adenocarcinoma in Japan (2018-2030)
Figure 43 Grade-specific Incident Cases of Gastro-esophageal Adenocarcinoma in Japan (2018-2030)
Figure 44 HER2 Positive Incident Cases of Gastro-esophageal Adenocarcinoma in Japan (2018-2030)
